Sugi Predict

Sugi Predict / Compounds / SCHEMBL821620

SCHEMBL821620

SCHEMBL821620

O=C(O)CNC(=O)c1c(O)c2ccccc2[nH]c1=O

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 8/20 0.76
▸ MEN1 O00255 7/20 0.76
▸ RXFP1 Q9HBX9 2/20 0.76
▸ KDM4E B2RXH2 8/20 0.73
▸ RAB9A P51151 7/20 0.70
▸ NPC1 O15118 6/20 0.70
▸ PKM P14618 1/20 0.70
▸ USP2 O75604 1/20 0.64
▸ SMN1; SMN2 Q16637 3/20 0.61
▸ NLRP3 Q96P20 1/20 0.61
▸ MAPT P10636 3/20 0.61
▸ ALDH1A1 P00352 3/20 0.61
▸ LMNA P02545 2/20 0.61
▸ NPSR1 Q6W5P4 2/20 0.61
▸ POLB P06746 2/20 0.60
▸ GAA P10253 1/20 0.59
▸ HTT P42858 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13598032 0.86 KMT2A (1.00) KMT2AMEN1RXFP1KDM4ERAB9A
SCHEMBL5304888 0.85 MEN1 (0.56) KMT2AMEN1RXFP1KDM4ERAB9A
SCHEMBL5309948 0.84 MEN1 (0.61) KMT2AMEN1RXFP1KDM4ERAB9A
SCHEMBL5311454 0.84 MEN1 (0.54) KMT2AMEN1RXFP1KDM4ERAB9A
SCHEMBL13598035 0.83 KMT2A (1.00) KMT2AMEN1RXFP1KDM4ERAB9A
SCHEMBL2086443 0.82 KDM5A (0.76) KMT2AMEN1RXFP1KDM4ERAB9A
SCHEMBL5312063 0.82 GSK3B (0.57) KMT2AMEN1RXFP1KDM4ERAB9A
SCHEMBL5305369 0.82 KDM4E (0.54) KMT2AMEN1RXFP1KDM4ERAB9A
SCHEMBL5312360 0.82 GSK3B (0.57) KMT2AMEN1RXFP1KDM4ERAB9A
SCHEMBL5308306 0.82 KDM4E (0.53) KMT2AMEN1RXFP1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007038571-A2 PROLYL HYDROXYLASE ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2007-04-05 — — WO claimed
CN-104427980-A Treatment for high cholesterol FIBROGEN INC 2015-03-18 — — CN disclosed
US-20140309256-A1 Therapeutic Method FIBROGEN, INC 2014-10-16 — — US disclosed
US-20140163061-A1 Methods For Reducing Blood Pressure FIBROGEN, INC. (US) 2014-06-12 — — US disclosed
WO-2013070908-A1 THERAPEUTIC METHOD FIBROGEN, INC. (US) 2013-05-16 — — WO disclosed
US-20110275697-A1 REGULATION OF CYCLIN D DANA FARBER CANCER INSTITUTE, INC. (US) 2011-11-10 — — US disclosed
US-20110039885-A1 METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS FIBROGEN, INC. (US) 2011-02-17 — — US disclosed
US-20110039879-A1 METHODS FOR INCREASING WHITE BLOOD CELLS FibroGen ,Inc. (US) 2011-02-17 — — US disclosed
US-20110039878-A1 METHODS FOR REDUCING BLOOD PRESSURE FIBROGEN, INC. 2011-02-17 — — US disclosed
CN-101917996-A Methods for reducing blood pressure FIBROGEN INC 2010-12-15 — — CN disclosed
EP-2231156-A1 METHODS FOR INCREASING WHITE BLOOD CELLS Fibrogen, Inc. (US) 2010-09-29 — — EP disclosed
EP-2227232-A1 METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION Fibrogen, Inc. (US) 2010-09-15 — — EP disclosed
EP-2222305-A1 METHODS FOR REDUCING BLOOD PRESSURE Fibrogen, Inc. (US) 2010-09-01 — — EP disclosed
US-20100144737-A1 METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION FIBROGEN, INC. (US) 2010-06-10 — — US disclosed
WO-2009102469-A2 REGULATION OF CYCLIN D DANA FARBER CANCER INSTITUTE, INC. (US) 2009-08-20 — — WO disclosed
WO-2009075822-A1 METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION FIBROGEN, INC. (US) 2009-06-18 — — WO disclosed
WO-2009075826-A1 METHODS FOR INCREASING WHITE BLOOD CELLS FIBROGEN, INC. (US) 2009-06-18 — — WO disclosed
WO-2009075824-A1 METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS FIBROGEN, INC. (US) 2009-06-18 — — WO disclosed
WO-2009058403-A1 METHODS FOR REDUCING BLOOD PRESSURE FIBROGEN, INC. (US) 2009-05-07 — — WO disclosed
WO-2007038571-A2 PROLYL HYDROXYLASE ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2007-04-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144737-A1 METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION NFATC1, CD4, IL2 KMT2A 2155/4885MEN1 4699/4885RXFP1 2961/4885
US-20110039879-A1 METHODS FOR INCREASING WHITE BLOOD CELLS THPO, MCL1, CD14 KMT2A 1277/4885MEN1 3386/4885RXFP1 3542/4885
US-20110039878-A1 METHODS FOR REDUCING BLOOD PRESSURE HMGCR, MB, PDE3A KMT2A 1388/4885MEN1 1631/4885RXFP1 784/4885
US-20110275697-A1 REGULATION OF CYCLIN D EGLN2, EGLN1, EGLN3 KMT2A 722/4885MEN1 2803/4885RXFP1 3878/4885
US-20140309256-A1 Therapeutic Method HIF1AN, EGLN3, EGLN2 KMT2A 714/4885MEN1 4028/4885RXFP1 1437/4885
US-20140163061-A1 Methods For Reducing Blood Pressure HMGCR, MB, PDE3A KMT2A 1388/4885MEN1 1631/4885RXFP1 784/4885
US-20110039885-A1 METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS CXCL12, SDF4, LIPG KMT2A 2124/4885MEN1 3856/4885RXFP1 2371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.